High rate of total cardiovascular and limb events in patients with peripheral artery disease

Introduction and methods

Background

Patients with peripheral arterial disease have an increased risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) [1]. However, most clinical trials report only the occurrence of first cardiovascular and limb events. Data on the total number – i.e., first and subsequent – events in patients with chronic stable symptomatic peripheral arterial disease are limited. Furthermore, it is unclear what the effect of treatment with ticagrelor or clopidogrel is on the total number of events in these patients. Previously, the EUCLID trial showed that the number of first events did not differ between patients with symptomatic peripheral arterial disease treated with ticagrelor or clopidogrel [2].

Aim of the study

The aim of this study was to investigate the total number of cardiovascular and limb events in patients with symptomatic peripheral arterial disease, both in the total study population and in specific subgroups.

Methods

The researchers conducted a post hoc analysis of data from the EUCLID trial. In this multicenter, double-blind RCT, patients ≥50 years of age with symptomatic peripheral arterial disease were randomized to treatment with ticagrelor (90 mg 2 dd) or clopidogrel (75 mg 1 dd). Symptomatic peripheral arterial disease was defined as lower extremity revascularization more than 30 days prior to randomization or ankle-brachial index ≤ 0.80. Key exclusion criteria included: long-term dual-antiplatelet therapy, requirement for aspirin, increased risk of bleeding, long-term anticoagulation treatment and poor clopidogrel metabolizer status.

Outcomes

The researchers reported the following acute cardiovascular and limb events: cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and acute limb ischemia, unstable angina, or TIA requiring hospitalization. In addition, they reported procedures, including coronary, carotid and peripheral revascularization and amputation for symptomatic peripheral arterial disease. Together, acute cardiovascular and limb events and procedures made up the total number of events.

Main results

• After a median follow-up of 2.7 years, a total of 7600 cardiovascular and limb events occurred in 13,885 randomized patients, including 3090 acute cardiovascular and limb events and 4510 procedures.
• The total number of events (n = 7600) was nearly double the number of first events (n = 3878).
• The incidence of all events was similar between the ticagrelor and clopidogrel groups (20.5 vs. 21.3 per 100 patient-years; HR: 0.96; 95%BI: 0.89-1.03; p = 0.27); a similar result was found for the incidence of acute cardiovascular and limb events and procedures separately.
• In addition, no statistically significant difference was found in the incidence of total MACE between the ticagrelor and clopidogrel groups (5.4 vs. 5.4 per 100 patient-years); a similar result was found for the incidence of total MALE (2.2 vs. 2.1 per 100 patient-years).
• None of the relative tests of heterogeneity were significant in subgroup analyses. However, these analyses revealed that the total number of cardiovascular and limb evens was especially high among patients with multiple affected vascular territories, patients with a history of coronary artery disease, and patients with prior peripheral revascularization.
• An association was found between the absolute risk of total cardiovascular and limb events and the number of affected vascular territories. Absolute risk reductions for ticagrelor vs. clopidogrel at 3 years were −0.2, 6.7, and 10.3 events per 100 patients for 1, 2, and 3 affected vascular territories, respectively (P for interaction = 0.09).

Conclusion

References

Find this article online at J Am Heart Assoc.